Analysts Set $5.10 Price Target for Fulgent Genetics Inc (FLGT)
Shares of Fulgent Genetics Inc (NASDAQ:FLGT) have received an average broker rating score of 3.00 (Hold) from the one analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating.
Brokers have set a 12 month consensus target price of $5.10 for the company and are predicting that the company will post ($0.01) EPS for the current quarter, according to Zacks. Zacks has also given Fulgent Genetics an industry rank of 168 out of 255 based on the ratings given to related companies.
FLGT has been the topic of a number of recent research reports. ValuEngine raised Fulgent Genetics from a “hold” rating to a “buy” rating in a research report on Saturday, July 14th. Piper Jaffray Companies reissued a “hold” rating and set a $5.10 price target on shares of Fulgent Genetics in a research report on Tuesday, August 7th. Credit Suisse Group dropped their price target on Fulgent Genetics from $6.00 to $5.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 9th. Finally, Zacks Investment Research raised Fulgent Genetics from a “hold” rating to a “buy” rating and set a $5.25 price target on the stock in a research report on Friday.
Fulgent Genetics (NASDAQ:FLGT) last posted its quarterly earnings results on Monday, August 6th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.02. Fulgent Genetics had a negative return on equity of 9.01% and a negative net margin of 30.93%. The business had revenue of $5.40 million for the quarter, compared to the consensus estimate of $4.97 million. research analysts forecast that Fulgent Genetics will post -0.18 earnings per share for the current fiscal year.
A hedge fund recently bought a new stake in Fulgent Genetics stock. Dimensional Fund Advisors LP acquired a new stake in shares of Fulgent Genetics Inc (NASDAQ:FLGT) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 26,809 shares of the company’s stock, valued at approximately $107,000. Dimensional Fund Advisors LP owned approximately 0.15% of Fulgent Genetics at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.11% of the company’s stock.
Fulgent Genetics Company Profile
Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, learning software, and genetic diagnostics tools and integrated laboratory processes.
Recommended Story: Book Value Per Share – BVPS
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.